Melanoma Institute Australia

What Melanoma Institute Australia does

Melanoma Institute Australia (MIA) is an independent non-profit medical research institute founded in 1960 (as the Sydney Melanoma Unit) and formally established in its current national-network form in 2010, headquartered at The Poche Centre in Wollstonecraft, NSW. It operates the world's largest dedicated melanoma research and treatment facility, treating approximately 2,000 new patients and conducting approximately 20,000 patient visits per year through affiliated specialty clinics covering surgical oncology, medical oncology, dermatology, radiation oncology, pathology and clinical psychology. The institute's research platform combines the world's largest melanoma patient database (MRD2, 50,000+ records dating to 1957) with the world's largest biospecimen bank (10,000+ patient-donated tissue samples), housed partly at the Charles Perkins Centre, University of Sydney, supporting 80+ research projects annually.

MIA's service portfolio spans clinical care, translational and clinical research, and clinician and patient education. Clinical research outputs are operationalised through an extensive clinical trials program, six online risk-prediction calculators, accredited learning modules via the Melanoma Education Portal, and clinical fellowships and observerships. The institute pursues a multi-channel go-to-market that combines GP and specialist referrals into affiliated clinics, distributed care via the federally funded National Melanoma Nurses Program (scaling to 35 FTE nurses by 2025-26), telehealth services, and partnerships with Melanoma Patients Australia for community support and webinars.

MIA's revenue model is a hybrid of clinical services revenue from affiliated specialist practices, Australian Federal and NSW Government grants (notably the $14.8M Nurses Program and $10M Screening Program), and philanthropy from individuals, corporate partners (La Roche-Posay, Macquarie, Hall Chadwick, MSD, BMS, among others), and major benefactors (notably the Poche family's $40M founding donation). Customer concentration is moderate, with a narrow set of large donors and public-sector funding anchors offsetting a high-volume, distributed patient base accessing services via clinician referral through Australia's public healthcare system.

Name

Melanoma Institute Australia

Legal name

Melanoma Institute Australia

Website

https://melanoma.org.au

Company type

Private

Founded year

1960

Operating status

Operating

Headcount range

51–100 employees

Short description

Melanoma Institute Australia is a non-profit medical research institute operating the world's largest melanoma research and treatment facility (The Poche Centre), combining multi-specialty clinical care, translational research, the world's largest melanoma database (50,000+ records) and biospecimen bank, and clinician education to advance its mission of zero deaths from melanoma by 2030.

Ownership category

akta.pro rank

Headquarters

HQ city

Sydney

HQ country

Australia

HQ region

Oceania

Offices4 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Donations and Philanthropy: As a non-profit organisation, MIA relies heavily on donations from individuals, corporations, and charitable foundations. Major donor Greg Poche AO and Kay Van Norton Poche AO provided a $40 million donation to build The Poche Centre. Corporate partners including La Roche-Posay, Macquarie, Hall Chadwick, and others contribute financially.
2. Government Funding: MIA receives funding from Federal and NSW Government bodies. The Federal Government committed $14.8 million for the Melanoma Nurses Program supporting 35 FTE nurses by 2025-26. The four-year Roadmap for National Targeted Melanoma Screening Program is Government funded commencing March 2025. The Australian Government allocated $10m for development of the National Targeted Skin Cancer Screening Program.
3. Clinical Services Revenue: Revenue generated from patient clinical services at affiliated clinics including surgery, medical oncology, radiation oncology, pathology, and dermatology across multiple specialist practices operating within The Poche Centre.

Pricing tiers

Go-to-market motion4 records

Distribution channels5 records

Marketing channels8 records

Core offering

MIA is a non-profit medical research institute that delivers multidisciplinary clinical care for melanoma and complex skin cancer patients via affiliated specialist practices at The Poche Centre. It runs a translational research program anchored by the world's largest melanoma patient database and biospecimen bank, an extensive Clinical Trials Program, and clinician-facing education resources (risk calculators, eBooks, accredited learning modules, fellowships, observerships). Patient services span the full journey from prevention and early detection through to advanced disease, survivorship and palliative care.

Product overview

Melanoma Institute Australia (MIA) is a non-profit medical research institute dedicated to preventing and curing melanoma through innovative research, treatment, and education. The organisation operates The Poche Centre as the world's largest melanoma research and treatment facility, providing clinical care through affiliated clinics including surgical oncology, medical oncology, dermatology, and psychology services. MIA's product portfolio includes clinical decision support tools (Risk Prediction Calculators), educational resources (eBooks, Melanoma Education Portal), patient support services (information guides, nursing support, psychology services), and research infrastructure (Melanoma Research Database, Biospecimen Bank, Clinical Trials Program). The institute also offers professional training through Fellowship Programs and Observership Programs for clinicians. MIA's services are structured around achieving zero deaths from melanoma through the three pillars of Research, Clinical Care, and Education.

Differentiator

Problem solved

Functional benefit

Products and services

• Sydney Melanoma & Surgical Oncology Affiliated specialist surgical oncology practice providing expert, research-based melanoma patient care including surgical oncology and radiation oncology services for melanoma and complex skin cancer patients at The Poche Centre.
• Sydney Medical Oncology Leading specialist oncology practice with internationally recognised experts providing the latest cancer treatments and access to clinical trials for melanoma and complex skin cancer patients.
• Melanoma Dermatology Clinic Affiliated nationwide referral centre for assessment and management of difficult pigmented lesions and melanoma, featuring state-of-the-art non-invasive diagnostic technology including confocal microscopy, optical coherence tomography, advanced dermoscopy and 3D total body photography.
• Clinical Psychology Service Short-term clinical psychological support and treatment service for patients with concerns related to melanoma diagnosis, treatment, survivorship or palliative care.
• Clinical Trials Program Extensive suite of clinical trials for patients with melanoma and other skin cancers, coordinated from The Poche Centre with trials conducted throughout the MIA affiliated network, including rural and regional sites.
• Risk Prediction Calculators Suite of six online clinical decision support tools for clinicians covering First Primary Melanoma Risk, Sentinel Node Metastasis Risk, Subsequent Primary Melanoma Risk, Thin Melanoma Recurrence Risk, Stage II Survival Prediction, and Immunotherapy Outcomes Prediction.
• Melanoma Education Portal Online education platform providing healthcare professionals with accredited learning modules, videos, podcasts, and clinical resources on melanoma diagnosis and treatment.
• Melanoma eBooks Interactive digital textbooks for clinicians and healthcare professionals including 'Melanoma Essentials: A Concise Guide' for GPs and 'Melanoma Principles & Practices' for specialists.
• Patient Information Guides Stage-specific guides for melanoma patients covering prevention, early detection, in-situ, stage I-II, stage III, and stage IV melanoma, available as free downloads.
• Fellowship Programs Clinical and research-based fellowships offering training in immuno-oncology, melanoma pathology, melanoma and surgical oncology, and dermatology for medical trainees and specialists.
• MIA Observership Program Educational observership program for clinicians to observe multidisciplinary best-practice melanoma care across disciplines including surgery, medical oncology, pathology, radiation oncology, and dermatology at The Poche Centre.
• Melanoma Research Database (MRD2) World's largest melanoma patient database containing records of over 50,000 patients dating back to 1957, supporting clinical trial development and national/international research collaborations in diagnosis, prognosis and treatment outcomes.
• Biospecimen Bank World's largest collection of melanoma tissue samples, donated by over 10,000 patients, paired with associated pathology reports and patient clinical data to support translational research and personalised diagnosis and treatment.
• National Melanoma Nurses Program Specialist melanoma nursing service providing direct care and support for melanoma patients throughout their treatment journey, with telehealth services extending reach to regional and rural areas.

Quantifiable outcome

• 5-year survival rate for advanced melanoma increased from <10% to >55%
• +3 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

18 partnerships are on record, tiered core and supporting.

• The University of SydneycoreStrategic or Co-development PartnerMIA is formally affiliated with The University of Sydney. The Institute's translational research laboratory is housed within the Charles Perkins Centre at the University. MIA's biospecimen bank and research database are used in collaboration with university researchers.
• Macquarie UniversitycoreStrategic or Co-development PartnerMIA collaborates with Macquarie University on clinical and research activities related to melanoma prevention, diagnosis and treatment.
• St Vincent's and Mater Health SydneycoreStrategic or Co-development PartnerClinical and research partnership with St Vincent's and Mater Health Sydney for melanoma patient care and research collaboration.
• Royal Prince Alfred HospitalcoreStrategic or Co-development PartnerMIA operates joint fellowship programs with Royal Prince Alfred Hospital including the RPAH/MIA Melanoma Pathology Fellowship. RPAH is a key clinical partner in the MIA network.
• Westmead HospitalcoreStrategic or Co-development PartnerClinical and research partnership with Westmead Hospital as part of MIA's network of hospital partners.
• QIMR Berghofer Medical Research InstitutecoreStrategic or Co-development PartnerResearch collaboration with QIMR Berghofer on melanoma research projects and scientific investigation.
• Sydney, Northern Sydney and Western Sydney Local Health DistrictscoreStrategic or Co-development PartnerPartnership with NSW Local Health Districts for clinical service delivery and research across the greater Sydney region.
• Melanoma Patients AustraliacoreStrategic or Co-development PartnerMIA works in close partnership with Melanoma Patients Australia (MPA) to provide patient education and support services nationally. Together they deliver the MPA-MIA Melanoma Community Webinar Series and monthly online support meetings. MIA also provides specialist melanoma nurse telehealth services in partnership with MPA.
• MSD AustraliasupportingGTM or Marketing PartnerMSD Australia supports MIA's education programs as an Education Program Supporter.
• Bristol-Myers SquibbsupportingGTM or Marketing PartnerBristol-Myers Squibb supports MIA's education programs as an Education Program Supporter and provided funding for the Melanoma Matters patient video series.
• La Roche-PosaysupportingGTM or Marketing PartnerLa Roche-Posay is a corporate partner of MIA providing support for melanoma research, education and patient support programs.
• MacquariesupportingGTM or Marketing PartnerMacquarie is a corporate partner of MIA contributing to melanoma research, education and support initiatives.
• Cancer Council NSWcoreStrategic or Co-development PartnerMIA has partnered with Cancer Council NSW and Cancer Institute NSW to run a Clinical Trials Pilot Financial Assistance program reducing travel and accommodation burdens for rural patients accessing clinical trials at MIA.
• Cancer Institute NSWcoreStrategic or Co-development PartnerIn partnership with Cancer Council NSW and Cancer Institute NSW, MIA runs a Clinical Trials Pilot Financial Assistance program to improve clinical trial accessibility for remote patients.
• Hall ChadwicksupportingGTM or Marketing PartnerHall Chadwick is a corporate partner of MIA providing pro-bono or supported services for melanoma research and awareness.
• First FoundationsupportingGTM or Marketing PartnerFirst Foundation is a corporate partner of MIA supporting melanoma research and patient programs.
• People TalkingsupportingGTM or Marketing PartnerPeople Talking is a corporate partner of MIA supporting melanoma awareness and research programs.
• HeinesupportingGTM or Marketing PartnerHeine is an Education Program Supporter for MIA's melanoma education programs.

Scale indicators8 records

Recent moves8 records

Expansion highlights6 records

Others

• Cancer Council Australia: Australia's peak national non-government cancer control organization supporting cancer prevention, research funding, and patient support. Comparable as an ecosystem partner that already collaborates with MIA via Cancer Council NSW on clinical trial financial assistance and national screening roadmap efforts.

Direct peers

• Melanoma Research Foundation: US-based non-profit organization dedicated to melanoma research, education, and patient advocacy, funding translational research and clinical trials. Comparable as a single-disease-focused melanoma non-profit combining research funding, education, and patient support.
• QIMR Berghofer Medical Research Institute: Large Australian medical research institute conducting translational and clinical research in cancer and other diseases, formally partnered with MIA on melanoma projects. Directly comparable as a translational medical research organization in Australia with biobanks and clinical trial programs.
• AIM at Melanoma: US-based non-profit dedicated to accelerating melanoma research and treatment through patient advocacy, scientific grants, and education. Comparable as a focused melanoma research and education non-profit with international ambitions.
• Peter MacCallum Cancer Centre: Australia's largest dedicated cancer research and treatment institution, operating as a hospital plus research institute with affiliated clinics, clinical trials, and translational research programs. Directly comparable as a flagship Australian cancer specialty provider integrating clinical care, research, and education.
• Chris O'Brien Lifehouse: Comprehensive cancer treatment and research hospital in Sydney offering surgical, medical, radiation oncology, supportive care, and clinical trial services. Comparable as a not-for-profit integrated cancer hospital/research center serving Sydney melanoma patients.
• Garvan Institute of Medical Research: Australian-based translational medical research institute affiliated with the University of New South Wales, focused on genomics, immunology, and cancer research. Comparable as a non-profit Australian research institute pairing laboratory discovery with clinical translation.

Broad incumbents

• Dana-Farber Cancer Institute: US-based principal teaching affiliate of Harvard Medical School focused on adult and pediatric cancer treatment and research, including a notable melanoma program. Comparable as a US-led cancer research and treatment incumbent operating across multiple cancer types including melanoma.
• Memorial Sloan Kettering Cancer Center: Largest US-based cancer hospital and research institute, operating a major melanoma service, large clinical trials program, and biobank. Comparable as a much broader incumbent with overlapping capabilities including translational melanoma research, clinical trials, and specialty outpatient services.
• MD Anderson Cancer Center: World-leading US cancer hospital and research institution with a substantial melanoma program and one of the largest oncology clinical trial portfolios globally. Comparable as a broad incumbent operating multi-disciplinary cancer care, research, and education at scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/MelanomaAus
• Facebookfacebook.com/MelanomaInstituteAustralia
• LinkedInlinkedin.com/company/melanoma-institute-australia
• Instagraminstagram.com/melainstituteau

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Melanoma Institute Australia